US FDA Proposes Excluding Semaglutide, Tirzepatide and Liraglutide from 503B Bulks List
The US Food and Drug Administration (FDA) proposes excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, citing no clinical need for compounding these GLP-1 drugs by outsourcing facilities.
Liraglutide | 04/05/2026 | By News Bureau
Biocon Launches its Glucagon-like Peptide-1 (GLP -1), Liraglutide in Netherlands
Biocon has launched its GLP-1 drug–device combination, Liraglutide, in the Netherlands, where it will be marketed under the brand names Diavorin for diabetes and Vobexoryn for chronic weight management.
Liraglutide | 15/12/2025 | By News Bureau | 190
Biocon Signs Semi-Exclusive Distribution and Supply Deal for with Medix
Biocon Ltd. has signed a semi-exclusive distribution and supply agreement with Medix, a specialty pharmaceutical company in Mexico, for the commercialization of its vertically integrated drug product, Liraglutide (gSaxenda).
Liraglutide | 13/05/2024 | By Aishwarya | 362
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy